Skip to main content

Table 4 Grade 3/4 events in the whole population (N = 248)

From: Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis

Toxicities

XELOX group

(N = 159)

DOS group

(N = 89)

P

leukocytopenia

6 (3.7)

3 (3.4)

0.848

Febrile neutropenia

1 (0.6)

0 (0)

0.768

thrombocytopenia

5 (3.1)

3 (3.4)

0.781

anemia

2 (1.3)

0 (0)

0.747

nausea

2 (1.3)

1 (1.1)

0.608

vomiting

1 (0.6)

1 (1.1)

0.747

diarrhea

1 (0.6)

0 (0)

0.768

hand-foot skin reaction

3 (1.9)

1 (1.1)

0.945

hepatic dysfunction

2 (1.3)

1 (1.1)

0.608

neuropathy

2 (1.3)

0 (0)

0.747

Mucositis

3 (1.9)

1 (1.1)

0.946